A proposal, backed by the Federal Trade Commission because it would save consumers money, would have banned patent settlements between brand-name and generic drug makers. But it was dropped from the health-care reform bill because it couldn’t pass muster with Congressional rules. School of Management Professor Michael Salinger, a former FTC director, the ban still should be enacted.
“So far, the courts have thwarted the FTC’s valiant efforts to end pay-for-delay. Whether or not it is included in the health-care overhaul, Congress should do so.”
Contact Michael Salinger, 617-353-4408, email@example.com